Alexis Battle is an Associate Professor at Johns Hopkins University with appointments in Biomedical Engineering , Computer Science , and Genetic Medicine (secondary). She directs the Malone Center for Engineering in Healthcare and serves as Deputy Director of the Data Science and AI Institute . Educated at Stanford University (PhD in Computer Science, 2013), Battle transitioned to academia after leadership roles at Google. Research Focus: Battle’s work bridges genomics and machine learning , emphasizing the impact of genetic variation on human health. Her lab develops tools like Watershed to predict functional effects of rare variants, aiming to enhance rare disease diagnosis. Key themes include non-coding DNA analysis , personalized genomics , and systems biology , with applications in cardiovascular disease and neurodegenerative disorders . Publications & Awards: Over 60 peer-reviewed articles in journals like Nature , Science , and Genome Biology , with recent emphasis on single-cell transcriptomics , multiomics integration , and telomere biology . Recipient of the President’s Frontier Award (2022), Microsoft Investigator Fellowship (2019), and Searle Scholar (2016). Scientific Awards: 2022 President’s Frontier Award 2019 Microsoft Investigator Fellowship 2019 Johns Hopkins Discovery Award 2017 Johns Hopkins Catalyst Award 2016 Searle Scholar Advising & Funding: Mentors 11 PhD students, 3 undergraduates, and postdoctoral fellows. Her research is funded by NIH, Searle Scholars, and institutional grants. The Battle Lab collaborates on projects like the GTEx Consortium , focusing on gene regulation and clinical genomics .
Harri Lähdesmäki is an Associate Professor (tenured) at the Department of Computer Science, Aalto University, where he leads the Computational Systems Biology research group. His work focuses on probabilistic machine learning and deep generative models with applications in biomedicine and molecular biology. Key Research Interests: Probabilistic machine learning, deep generative models, computational biology, bioinformatics, longitudinal data modeling Contact: harri.lahdesmaki@aalto.fi | Konemiehentie 2, 02150 Espoo, Finland His recent publications highlight advancements in: Gaussian process priors for scalable deep generative models Single-cell analysis of immune repertoires in leukemia and diabetes Probabilistic deconvolution methods for RNA-seq data Epigenetic analysis using hidden Markov and mixed models Transformer-based survival prediction and missing data handling Harri’s work integrates mechanistic modeling with Bayesian inference, particularly applied to immunology, cancer biology, and early disease prediction.
Konstantinos Anastassiadis is a Professor at the Center for Molecular and Cellular Bioengineering (CMCB) of Dresden University of Technology , leading the Stem Cell Engineering group at the Biotechnology Center (BIOTEC) . His research focuses on unraveling molecular pathways regulating stem cell self-renewal and lineage commitment, with a strong emphasis on genetic engineering tool development and epigenetic mechanisms during cellular reprogramming. The lab utilizes mouse and human embryonic stem cells, neural stem cells, mesenchymal stromal cells, and induced pluripotent stem cells (iPSCs) in their investigations. Core Research Areas: Molecular regulation of stem cell fate Epigenetic mechanisms (e.g., UTX/UTY histone demethylases) Genetic engineering tool development (Flp, Dre, Vika recombinases, CRISPR protocols) Conditional immortalization systems for rare cell expansion Publications highlight his contributions to understanding: Role of histone methyltransferases (MLL1, MLL2, Setd1b) in hematopoiesis and cancer Epigenetic regulation during mouse development and spermatogenesis Genetic tools for protein tagging, transposon-mediated BAC transgenesis Interactions between stem cells and niche microenvironments Transcriptional and mechanical markers during reprogramming Collaborations span immunology , developmental biology , and bioinformatics . The lab actively participates in teaching activities at CMCB and maintains a focus on translational applications of stem cell research.
Professor Marek Sanak serves as Full Professor at the Department of Internal Medicine, Jagiellonian University Medical College in Cracow, Poland. He concurrently holds leadership positions as Acting Director of the Department of Forensic Medicine, Head of the Division of Molecular Biology and Clinical Genetics, and Vice-Rector for Research and International Cooperation since 2016. His academic foundation includes: MD from Jagiellonian University Medical College Specialization in Pediatrics and Genetics PhD from Jagiellonian University Research appointments at Harvard University, University of Paris VI, and University of Zurich Professor Sanak's research integrates clinical genetics with molecular immunology, focusing on asthma pathogenesis, lipid mediators of inflammation, and genetic diagnostics. His laboratory employs advanced techniques including deep DNA/RNA sequencing to identify biomarkers and elucidate disease mechanisms. The work bridges fundamental molecular discoveries with clinical applications in respiratory diseases, allergic disorders, and forensic medicine, demonstrating particular expertise in aspirin-exacerbated respiratory disease and epigenetic regulation of inflammatory pathways. Analysis of his recent publications reveals a strategic evolution from classical asthma research toward molecular genetics and viral pathogenesis. His 2017-2021 work increasingly incorporates epigenetic approaches (DNA methylation, microRNA profiling) while expanding into SARS-CoV-2 research during the pandemic. The publications demonstrate interdisciplinary integration across immunology, respiratory medicine, and molecular diagnostics, with consistent focus on translational applications. His distinguished career has been recognized through numerous honors: The Lancet Investigators Award on Asthma (1997) Polish Ministry of Health Individual Prize (1999) Jagiellonian Laurel (2012) Pro Arte Docendi Award (2014/15) Gold Medal for Long Service (2019) Top 2% of world scientists ranking (Elsevier 2022) As Vice-Rector for Research, Professor Sanak has significantly expanded international collaborations with King's College London, University of Southampton, and University of Zurich. His leadership has secured substantial funding for molecular diagnostics and inflammatory disease research while mentoring numerous early-career researchers. He delivers invited lectures globally for organizations including the American Thoracic Society and European Academy of Allergy and Clinical Immunology. Professor Sanak directs integrated research units across the Division of Molecular Biology and Clinical Genetics, Division of Biochemical and Molecular Diagnostics at University Hospital Cracow, and the Department of Forensic Medicine. These teams combine clinical service with basic research to advance genetic diagnostics and understand disease mechanisms, maintaining forensic genetics expertise developed over 20 years of practice.
David Serre is a Professor in the Department of Microbiology and Immunology at the University of Maryland School of Medicine, with an additional appointment at the Institute for Genome Sciences. His research focuses on developing genomic approaches to study eukaryotic pathogens, particularly Plasmodium vivax, the leading cause of malaria outside Africa. His laboratory investigates parasite responses to antimalarial drugs, host immune responses, and mosquito vector biology using genomic and transcriptomic techniques. Education 1997–2000: Engineering degree in Chemistry, École Nationale Supérieure de Chimie, Montpellier, France 2000–2004: PhD in Biology, Max Planck Institute for Evolutionary Anthropology, Leipzig, Germany 2004–2007: Postdoctoral fellowship, McGill University and Genome Quebec Innovation Centre, Montreal, Canada Research Focus Dr. Serre’s work integrates genomics to study Plasmodium vivax’s drug resistance, relapse mechanisms, and interactions with hosts and vectors. Key areas include: Genomic assays to characterize parasite drug responses Transcriptomic analysis of host immune responses Genomic studies of Anopheles mosquitoes as malaria vectors Recent Trends in Publications Recent work highlights genomic and transcriptomic approaches to dissect Plasmodium vivax biology, including: Single-cell RNA sequencing to resolve transcript isoforms and stage-specific expression Analysis of relapse dynamics and drug resistance mechanisms Microbiome studies in mosquitoes and environmental contexts Grants & Advising No explicit grants or advisee names are listed in the provided text. Collaborators include institutions like the Max Planck Institute, McGill University, and the Institute for Genome Sciences. Labs & Teams His lab is affiliated with the University of Maryland School of Medicine and the Institute for Genome Sciences, focusing on genomic and molecular approaches to infectious diseases.
Dr. Gabriele Schweikert is a Senior Lecturer and Principal Investigator with a joint appointment between the Division of Computational Biology in the School of Life Sciences at University of Dundee and Cyber Valley in Tuebingen. Her research focuses on applying machine learning techniques to understand epigenetic mechanisms and molecular processes in living cells. Dr. Schweikert completed her PhD at the Max Planck Institute Tuebingen working with Schoelkopf, Weigel, and Raetsch labs on machine learning for computational gene finding. She subsequently joined Adrian Bird's lab at the Wellcome Trust Center for Cell Biology in Edinburgh, a pioneer in epigenomic research. Prior to her current position, she held prestigious Marie Curie and EMBO Fellowships at the School of Informatics, University of Edinburgh. Her research interests center on using machine learning to decode epigenetic mechanisms that determine cellular identity and function. She investigates how cells with identical DNA can differentiate into specialized cell types through epigenetic regulation, with particular focus on applications in understanding tumorigenesis where epigenetic machinery malfunctions. Her work combines high-throughput epigenomic data with advanced computational approaches to address complex biological questions. Analysis of her recent publications reveals a strong focus on epigenomic data analysis, machine learning applications in biology, and computational approaches to understanding gene regulation. Her work spans from fundamental epigenetic mechanisms to practical applications in disease research, with growing emphasis on individual-specific epigenomic analysis and explainable AI in biomedical contexts. UKRI Future Leaders Fellowship (2020, £1.6 million) Marie Curie Fellowship EMBO Fellowship Dr. Schweikert actively supervises PhD students and has received significant research funding for projects including 'Machine Learning Methods to Re-Annotate Histone Modifications,' 'Unlocking The Alternative Splicing Code,' and 'GPU-Based Machine Learning System For Fundamental Biological Research.' She is involved in multiple interdisciplinary collaborations and frequently presents her work at major conferences including ELLIS Health program retreat, Epigenetics Meetings, and RECOMB workshops. She maintains active research laboratories in both Dundee and Tuebingen, fostering international collaboration between computational biologists, machine learning experts, and experimental biologists to advance our understanding of epigenetic regulation in health and disease.
Peter A. Jones is President and Chief Scientific Officer at the Van Andel Institute (VAI) in Grand Rapids, Michigan, where he leads the Department of Epigenetics. He previously served as Director of the USC Norris Comprehensive Cancer Center from 1993 to 2011 and has been a central figure in advancing epigenetics research, particularly in cancer. His laboratory investigates DNA methylation, chromatin dynamics, and epigenetic therapies. Research Interests: Dr. Jones's work centers on epigenetic mechanisms in cancer, including DNA methylation, histone modifications, nucleosome positioning, and the therapeutic potential of epigenetic drugs. His research has pioneered the use of DNA methylation inhibitors like 5-azacytidine and explored viral mimicry as a mechanism for immune activation in cancer. He also studies transposable elements and their role in gene regulation and immune response. Publication Trends: His recent publications (2021–2024) reveal a strong focus on the interplay between epigenetics and immunotherapy, particularly how DNA methyltransferase inhibitors (DNMTi) induce viral mimicry, enhance immune recognition, and improve responses to checkpoint blockade. Studies span hematological malignancies, solid tumors, and T cell biology, with frequent collaboration with Stephen Baylin and others. Scientific Awards: Member, National Academy of Sciences Member, National Academy of Medicine Fellow, AACR Academy Fellow, AAAS Fellow, American Academy of Arts and Sciences Kirk A. Landon Award for Basic Cancer Research (2009) Medal of Honor, American Cancer Society (2011) Outstanding Investigator Grant, NCI Harvey Prize (2024) Advising and Grants: Dr. Jones mentors multiple postdoctoral fellows, graduate students, and research scientists. His lab is supported by major grants, including the VAI-SU2C Epigenetics Dream Team, which has launched 15 clinical trials. He has received sustained funding from the National Cancer Institute and collaborates with institutions worldwide to advance epigenetic therapies. Labs and Teams: He leads the Peter Jones Laboratory at VAI, a multidisciplinary team investigating epigenetic regulation in cancer. The lab includes computational biologists, clinical researchers, and molecular biologists, working on both basic mechanisms and translational applications. The team is part of larger collaborative initiatives such as the VAI-SU2C Epigenetics Dream Team and the International Linked Clinical Trials Program.
Adrian Linacre is a Professor and Chair in Forensic DNA Technology at Flinders University, within the College of Science and Engineering, Department of Biological Sciences. He is a leading figure in forensic science, with a focus on DNA analysis, wildlife forensics, and crime scene investigation. BSc in Biological Sciences (Hons), University of Edinburgh, 1984 DPhil in Molecular Genetics, University of Sussex, 1988 His research centers on getting more from less at crime scenes , particularly through developing highly sensitive DNA typing methods and studying the transfer and persistence of biological materials. He also pioneers the use of non-human DNA in forensic investigations, notably in wildlife forensic science , aiding in species identification and combating illegal wildlife trade. His recent publications reflect a strong trend in trace DNA analysis , body fluid identification , and DNA transfer dynamics , with applications in drug cases, sexual assault investigations, and environmental DNA degradation. His work increasingly integrates molecular techniques with real-world forensic challenges. Notable scientific awards include: Medal of the Order of Australia (OAM), 2020 Inspirational Scientist of the Year, Royal Society of Edinburgh, 2005 Fellow of the Royal Society for the Encouragement of Arts and Commerce (FRSA) Finalist, South Australian Science Excellence and Innovation Awards (2023, 2024) He has successfully supervised several students, including Piyamas Kanokwongnuwut and Alicia Haines, many of whom have won international recognition. He has secured significant research funding and contributed to national and international forensic policy, including a key review for the UK Home Office on low-template DNA. His professional leadership includes presidencies of the ANZFSS and ISFG, and vice presidency of the IAFS. Linacre is actively involved in editorial roles, serving as Associate Editor for Forensic Science International: Genetics and on the boards of Forensic Science, Medicine and Pathology and the Australian Journal of Forensic Science . He is a sought-after expert witness and media commentator in forensic science.
Maria Timofeeva is an Associate Professor in the Epidemiology, Biostatistics and Biodemography (EBB) department at the University of Southern Denmark (SDU), with additional affiliation at the Danish Institute for Advanced Study (DIAS). She holds an Honorary Fellow position at the University of Edinburgh since December 2019. Her research focuses on cancer prevention and prediction, particularly studying the effects of environmental and genetic factors on cancer risk and progression. Dr. Timofeeva earned her Dr.sc.hum in Epidemiology from Heidelberg University (2005-2009), with a dissertation on genetic polymorphisms as risk factors for early onset lung cancer. Prior to her current position, she worked as a Statistical Geneticist at the University of Edinburgh (2013-2019) and as a Postdoctoral Fellow at the International Agency for Research on Cancer (2009-2013). Her research interests center around understanding the genetics of cancer risk through multi-omic analysis. She leads several significant projects, including the Interdisciplinary Project on Adherence to Colorectal Cancer Screening, meta-analysis of factors associated with false-positive and false-negative FOBT results (registered in PROSPERO ID: CRD42022315767), and the COlorectal Cancer screening Among RElatives (CoCARE) twin-family study in Denmark. Her methodological expertise spans observational epidemiological studies (case-control, population-based cohort studies, twin studies), meta-analysis, umbrella reviews, and multi-omics data analysis. Analysis of her recent publications reveals a strong focus on colorectal cancer genetics, with particular emphasis on genome-wide association studies, Mendelian randomization approaches, and trans-ancestry analyses. Her work frequently leverages large datasets including the UK Biobank and international consortia, with applications in cancer risk prediction and understanding gene-environment interactions. Dr. Timofeeva has an extensive publication record with 73 publications listed in her profile. Her research has been cited across multiple platforms, with mentions in news outlets, social media, and academic readership platforms like Mendeley. She is actively involved in academic service, serving as a peer reviewer for journals including BMC Cancer and Scientific Reports, and participating in conferences such as the 26th Nordic Congress of Gerontology. She also serves on evaluation committees, including with the World Cancer Research Fund International (April-May 2024). Her teaching activities include courses on evidence-based drug utilization and biostatistics, as well as supervision of research projects on gene expression in twins. Dr. Timofeeva has engaged with the public through media contributions, including an interview titled 'Jeg vil forstå, hvorfor vi får kræft' (November 15, 2021), where she discussed understanding why we get cancer.
Sara Hägg is a Senior Lecturer at the Karolinska Institutet , affiliated with the Department of Medical Epidemiology and Biostatistics . She is also a Docent in molecular epidemiology. PhD in Computational Biology (Linköping University, 2009) MSc in Molecular Biology (Stockholm University, 2003) BSc in Computer Science (Stockholm University, 2003) Her research focuses on human biological aging , including measurement of aging markers (telomere length, epigenetic clocks, frailty index), causal pathway analysis, and identification of geroprotectors for age-related diseases. She utilizes longitudinal twin studies (SATSA, GENDER, HARMONY), UK Biobank, and Swedish cohorts with methods like Mendelian randomization and genome-wide analyses . Recent articles demonstrate trends in epidemiological aging research , with emphasis on cardiovascular aging , neurological disease interactions , metabolic profiling , and epigenetic clocks . Her work often involves multivariable modeling and cross-cohort validation . Leadership roles include Director of LifeGene Core Facility (2024-) and Founding Board Member of the Nordic Aging Society (2023-). She serves on expert groups for the Swedish Twin Registry and Strategic Research Area in Epidemiology and Biostatistics .
Brock C Christensen is a Professor at the Geisel School of Medicine , Dartmouth, affiliated with the Departments of Epidemiology , Community and Family Medicine , and Molecular and Systems Biology . His research integrates molecular biology, genomics, and bioinformatics with epidemiology to investigate epigenetic mechanisms in human health and disease. Harvard University, PhD (2008) University of Wisconsin - Madison, BS (2002) Dr. Christensen's work focuses on epigenetic susceptibility traits , environmental interactions, and translational applications in cancer diagnostics and treatment. His recent publications explore DNA methylation patterns in triple-negative breast cancer , head and neck cancer , and pediatric CNS tumors . He serves as course director for PEMM103: Introductory Applied Biostatistics with R and leads the Christensen Lab , which specializes in epigenomic profiling and computational biology.
Karestan C. Koenen is Professor of Psychiatric Epidemiology at the Harvard T.H. Chan School of Public Health and an Associate Member at the Broad Institute of MIT and Harvard . She also serves as Affiliated Faculty at the Harvard University Center for the Environment , advising students in Epidemiology and Social Behavioral Sciences. BA in Economics, Wellesley College MA in Developmental Psychology, Columbia University PhD in Clinical Psychology, Boston University Post-doctoral Fellowship in Psychiatric Epidemiology, Columbia University Dr. Koenen's research focuses on three areas: (1) understanding PTSD resilience, (2) trauma's long-term physical health impacts, and (3) expanding access to evidence-based mental health treatments. Her work bridges genetics, global mental health, and trauma epidemiology, with recent studies on epigenetic aging, cognitive outcomes after trauma, and substance use comorbidities. Her 2025 publications span psychiatric genetics, trauma neurobiology, and women's health, emphasizing machine learning, neuroimaging, and population-level interventions. Current projects include the Broad Trauma Initiative and NIMH-funded training programs. 2025 Junior Faculty Mentoring Award 2021 Pamela Sklar Innovation Award 2017 Distinguished Alumnae Award 2015 Robert S. Laufer Memorial Award Dr. Koenen actively trains graduate students through the Trauma Epidemiology and Population Mental Health Research Group . She integrates advocacy into her work, having testified before Congress and consulted on documentaries about trauma, while publishing in outlets like the Boston Globe and Psychology Today . Her lab collaborates on mental health policy and global trauma research.
Prof. Dr. med. Franz Lennard Ricklefs is a Senior Physician and Head of the Working Group at the Department of Neurosurgery, University of Hamburg Faculty of Medicine. He is a Medical Specialist in Neurosurgery with cross-disciplinary expertise in neuro-oncology, molecular pathology, and extracellular vesicle research. Affiliations: University Medical Center Hamburg-Eppendorf (UKE), European Liquid Biopsy Society (ELBS), International Consortium on Meningiomas (ICOM) Research Interests: His work focuses on neurosurgical oncology, particularly glioblastoma and meningioma pathobiology. He investigates DNA methylation patterns, extracellular vesicle biomarkers, and liquid biopsy implementation in clinical neuro-oncology. Additional interests include surgical outcomes for epilepsy and aneurysm management. Article Trends: Over the last decade, Dr. Ricklefs has published extensively on: Extracellular vesicle applications as liquid biopsy markers DNA methylation subclasses for glioblastoma and meningioma Multicenter surgical outcome benchmarking Immune evasion mechanisms in neuro-oncology Technological innovations in neurosurgical visualization Molecular characterization of rare CNS tumors Professional Contributions: He co-authored the MISEV2023 guidelines for extracellular vesicle studies and participates in international consensus reviews for meningioma classification. His collaborations span institutions across Europe and North America.
Dr. Ed E. Moret is an Associate Professor of Computational Medicinal Chemistry at Utrecht University, where he serves as Managing Director of the Utrecht Institute for Pharmaceutical Sciences. He is a member of the Departmental Executive Board and Chair of the Board of Examiners of the School of Pharmacy. His academic career spans over three decades with significant contributions to pharmaceutical sciences. Utrecht University, Utrecht Institute for Pharmaceutical Sciences School of Pharmacy, Department of Chemical Biology and Drug Discovery Managing Director since January 2010 Dr. Moret's educational background includes completing Gymnasium-b at Gymnasium Camphusianum in Gorinchem in 1979, followed by pharmacy studies at Utrecht University until 1988. He earned his PhD in 1993 with research on calculations and simulations of DNA-alkylating cytostatics under supervision of Prof. L.H.M. Janssen and Prof. J.P.A.E. Tollenaere. He also conducted postdoctoral research at the Scripps Research Institute with Prof. A.J. Olson. His primary research interests focus on molecular recognition, particularly in auto-immune diseases, with expertise spanning computational medicinal chemistry, computer-aided drug discovery, cheminformatics, and bioinformatics. Dr. Moret's work bridges the gap between theoretical calculations and experimental validation in drug design. His research portfolio demonstrates a consistent trajectory from fundamental molecular interactions to applied drug discovery, with particular emphasis on enzyme inhibitors, carbohydrate-protein interactions, and molecular recognition processes. Analysis of his publication record reveals a strong focus on structure-based drug design, with significant contributions to the development of inhibitors for enzymes like β-glucocerebrosidase, NNMT, and neuraminidase. His work spans multiple therapeutic areas including lysosomal storage disorders, cancer metabolism, and infectious diseases. The interdisciplinary nature of his research is evident in the integration of computational approaches with experimental validation across biochemistry, pharmacology, and medicinal chemistry. Teacher of the Year (awarded three times by Pharmacy students) Member of editorial boards for Medicines and Conceptuur journals Secretary of Board of FIGON (2016) Secretary of Raad voor de Farmaceutische Wetenschappen (2024) Member of Board of Stichting Farmaceutische Erfgoed (2024) Dr. Moret has been actively involved in educational innovation, developing and coordinating the master's programme Drug Innovation, the profile Drug Regulatory Sciences, and the Honours programme Pharmaceutical Sciences. He has taught courses for pharmacy, chemistry, UCU and medical sciences students, as well as PhD courses in bioinformatics and computer-aided drug discovery. His educational contributions include developing an inquiry-based elective course on drug discovery, for which he published educational research. He holds BKO and SKO teaching qualifications and participated in the Centre of Excellence in University Teaching program. As Managing Director of the Utrecht Institute for Pharmaceutical Sciences, Dr. Moret leads research initiatives across chemical biology, drug discovery, and pharmaceutical sciences. His leadership extends to multiple advisory and editorial roles within the pharmaceutical research community, reflecting his significant contributions to both academic and professional spheres of pharmaceutical sciences.
Simon Crouch is a Senior Research Fellow in Biostatistics at the University of York's Health Sciences department. With a strong mathematical background from Cambridge and Warwick, he leads the analytics team within the Epidemiology and Cancer Statistics Group and works closely with the Haematological Malignancy Research Network (HMRN) and Cardiovascular Health team. His work focuses on statistical modeling of complex epidemiological data related to hematological malignancies. University of Cambridge: MA, MMath in Mathematics University of Warwick: PhD in Mathematics University of Lancaster: MSc in Medical Statistics Dr. Crouch specializes in the statistical modeling of complex epidemiological data, with particular focus on hematological malignancies. His research encompasses predictive modeling, event history analysis, and machine learning applications in cancer epidemiology. He has made significant contributions to understanding myelodysplastic syndromes, lymphoma classification, and survival analysis in blood cancers through population-based studies. His work often involves collaboration with international registries including the European Myelodysplastic Syndromes Registry (EUMDS) and the Haematological Malignancy Research Network. Analysis of his recent publications reveals a strong focus on myelodysplastic syndromes (MDS), with particular attention to risk stratification, survival analysis, and treatment outcomes. His work increasingly incorporates genomic and molecular data to refine disease classification and prediction models. The trend shows progression from purely statistical methodology development toward integrated translational research that combines clinical, genomic, and epidemiological data to improve patient outcomes. Extensive publication record with 113 research outputs including 66 articles, 21 patents, and numerous meeting abstracts Active participation in major international research consortia including MDS-RIGHT and ImmunAID Significant contributions to the development of statistical methodologies for cancer epidemiology Dr. Crouch actively supervises PhD students in mathematical and statistical modeling applied to cancer epidemiology, with particular interest in time-to-event models, complex longitudinal models, and simulation techniques. His research has been supported through multiple projects, including the European Myelodysplastic Syndromes Registry and the MDS-RIGHT project focused on facilitating informed decision-making in hemato-oncology. He contributes to the Advanced Health and Social Statistics module for postgraduate students at the University of York.
